By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eiger Biopharma 

Palo Alto  California    U.S.A.
Phone: n/a Fax: n/a


Start Up

Company News
Eiger Biopharma Announces Results Demonstrating Benefit Of Ubenimex And Leukotriene B4 (LTB4) Modulation In Experimental Lymphedema 5/17/2017 6:55:13 AM
Eiger Biopharma Completes Enrollment Of Phase II LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension 5/15/2017 6:31:54 AM
Eiger Biopharma Reports First Quarter 2017 Financial Results 5/12/2017 10:06:23 AM
Eiger Biopharma Announces Presentation Of Prevalence Data Of Hepatitis Delta Virus (HDV) Infection In The U.S. At Digestive Disease Week (DDW) In Chicago 5/8/2017 7:27:50 AM
Eiger Biopharma Announces U.S. IND Filing Of Pegylated Interferon Lambda For Hepatitis Delta Virus Infection 5/3/2017 7:50:06 AM
Eiger Biopharma Announces Additional Phase II Clinical Trial Results For Lonafarnib At The International Liver Congress 2017 4/21/2017 6:44:01 AM
Eiger Biopharma Announces Industry Veteran Lisa Porter, M.D. To Lead Development Of Exendin 9-39 For The Treatment Of Post-Bariatric Hypoglycemia 4/18/2017 9:09:37 AM
Eiger Biopharma Reports Fourth Quarter And Full Year 2016 Financial Results 3/23/2017 11:42:24 AM
Eiger Biopharma Completes $25 Million Debt Financing With Oxford Finance 1/4/2017 8:41:13 AM
Eiger Biopharma Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH) 1/3/2017 6:44:47 AM